Among all existing radionuclides, only a few are of interest for therapeutic applications and more specifically for targeted alpha therapy (TAT). Actinium-225, astatine-211, bismuth-212, bismuth-213, lead-212, radium-223, terbium-149 and thorium-227 are considered as the most suitable. Despite common general features, they all have their own physical characteristics that make them singular and so promising for TAT. These radionuclides were largely studied over the last two decades, leading to a better knowledge of their production process and chemical behavior,
allowing for an increasing number of biological evaluations. The aim of this review is to summarize the main properties of these eight chosen radionuclides. An overview from their availability to the resulting clinical studies, by way of chemical design and preclinical studies is discussed.
Actinium is the first element of the actinide series, and among its 32 known isotopes, only 228Ac and 227Ac occur naturally as part of the decay chains of 232Th and 235U, respectively. 227Ac is the most abundant isotope, exhibiting a long half-life of 21.7 years and decaying mainly through β− emissions. 228Ac is also a β− emitter and is extremely rare. 225Ac is part of the 237Np decay chain which has disappeared in Nature but was recreated artificially. 225Ac exhibits features that have made it a promising candidate in nuclear medicine applications. It has a half-life of 9.9 days. Its disintegration follows a six-step decay chain to reach stable nuclei, that generates multiple alpha particles contributing to increasing its potential cytotoxicity in comparison with other α-emitters (Figure 1). Besides, with the γ-emission of some of its daughter nuclides such as 221Fr or 213Bi, it provides the possibility to trace it after injection. Nevertheless, it has to be mentioned that these radiations make the reaction monitoring difficult and the secular equilibrium has to be reached before one can measure a reliable radiochemical yield (at least 6 h).
Figure 1. Decay schemes for the production of 225Ac and 213Bi.
Astatine is often reported as the rarest natural element on Earth, and exhibits 32 isotopes, none of them being stable. Even if most of these isotopes are α-emitters, only 211At exhibits suitable physical properties for TRT. It decays with a half-life of 7.21 h and following a dual branch process resulting in the emission of 5.9 and 7.5 MeV α particles as well as X-rays (77–92 keV). Whatever the branch, one alpha particle is emitted, qualifying 211At as a 100% α-emitter. It is interesting to notice that potential radiotoxicity of 211At daughters’ is negligible; especially because of the short half-life of 211Po and the very low amount of 207Bi generated. Finally, the emission of X-rays in the adapted energy range of common γ-detectors, offers the possibility of monitoring by single photon emission computed tomography (SPECT) imaging (Figure 3).
Figure 3. Simplified decay scheme of 211At.
Bismuth belongs to group 15 of periodic classification and exhibits 35 isotopes, most of them having short half-lives (from ns to a few minutes) and only one is considered stable, 209Bi, due to a very long half-life of 1.9 × 1019 years. Among all these isotopes, only 212Bi and 213Bi have demonstrated promising features for investigation in targeted alpha therapy.
213Bi, a daughter isotope of 225Ac, decays by α (2.2%) and β− (97.8%) emission with a half-life of 46 min. It decays to the stable 209Bi via successive decays resulting in β− emissions (0.6–2 MeV) and the emission of one α particle (5.9–8.4 MeV). The total emitted energy of 213Bi can be attributed at 90% to α-particles and can explain its more pronounced cytotoxicity. In addition, the emission of gamma rays with an energy of 440 keV offers the possibility of imaging by SPECT (Figure 1).
212Bi arises from the decay sequence of 228Th (1.9 y) and results in 208Tl (3.1 min) via 36% of α-emission and by 64% to 212Po (0.3 µs) after β−-emission, both daughters leading to stable 208Pb. 208Tl decay occurs through high energy γ-emission (2.6 MeV), which necessitates adapted protection for all the handling phases. Like 213Bi, 212Bi exhibits a short half-life (60.6 min) which requires rapid targeting as well as efficient production of radiolabeled carrier molecules. On the other hand, in vivo release issues regarding 212Bi daughter radionuclides are negligible due to the short decay chain of 212Bi to stable 209Bi and the short half-lives of the daughters induced (Figure 6).
Figure 6. Decay schemes for the production of 212Bi and 212Pb.
Lead is often presented as the heaviest stable element in the periodic classification and exhibits four stable isotopes: 204Pb, 206Pb, 207Pb and 208Pb. Among its 38 reported isotopes, five would have appropriate properties for detection (203Pb, 210Pb, 211Pb, 212Pb, 214Pb) but only two are suitable for clinical application, in imaging with 203Pb (SPECT) and therapy with 212Pb. 212Pb is a β-emitter but its interest in TAT comes from the fact that its first daughter is 212Bi (Figure 6). The short half-life of 212Bi can be overcome by using 212Pb in vivo generator of 212Bi.
Radium is an alkaline earth metal originating from the decay process of 235U, 238U or 232Th. Among its 33 known isotopes, only four occur naturally: 228Ra (5.75 y) and 224Ra (3.63 d) from 232Th, 226Ra (1600 y) the most abundant, from 238U (stable) and 223Ra (11.4 d) from 235U (703,800,000 y). 223Ra and 224Ra are both α-emitters but the decay chain of 224Ra includes daughter nuclides such as 220Rn (56 s) and 212Pb (10.6 h) with non-negligible half-lives that could be problematic because of their potential redistribution in the whole organism. Therefore, 224Ra has been much less investigated than 223Ra, mainly for treatment of noncancerous bone diseases, encapsulation in particles or as generator of 212Pb.
223Ra decays to 219Rn (3.96 s), 215Po (1.78 ms), 211Pb (36.1 min), 211Bi (2.14 min), 207Tl (4.77 min) or 211Po (0.52 s) and stable 207Pb. This long disintegration sequence generates four high energy α particles, two β- particles and γ rays conducing to a total energy emitted around 28 MeV. The cascade of α particles generated (around 96% of the total energy) allows to increase the radiation dose received by the targeted tissues, whereas low energy γ component (269 keV) is of interest for monitoring (Figure 8).
Figure 8. Decay schemes for the production of 223Ra and 227Th.
Terbium is a rare-earth metal with only one stable isotope, 159Tb, whose physico-chemical properties are interesting for the development of fluorescent complexes. This element is also described as the “Swiss army knife of nuclear medicine” because among its thirty-six isotopes reported, four of them exhibit suitable properties to cover all modalities in nuclear medicine: 152Tb (17.5h, Eβ+ = 1.08 MeV) for positron emission tomography (PET), 155Tb (5.32d, Eγ = 86.55 keV) for SPECT and Auger electron therapy, 149Tb (4.1h, Eα = 3.97 MeV) and 161Tb(6.89 d, Eβ- = 0.154 MeV) for therapy. 149Tb decays to several radiolanthanides by emission of low energy α (3.97 MeV, 17%), electron capture (76%), and β+ particles emission (730 keV, 7%), making it interesting for TAT and a possible follow-up by PET. It has to be mentioned that the potential radiotoxicity of the daughter isotopes (long half-life) generated is still to be determined (Figure 9).
Figure 9. Decay scheme of 149Tb.
Thorium is a metal of the actinide series whose isotopes are all radioactive. Natural thorium exists almost exclusively as 232Th and to a lesser extend 230Th. Thorium isotopes exhibit mostly very short (few μs or ms) or long (few years) half-lives and only two exhibit a potential for TAT: 226Th (30.6 min) and 227Th (18.7 days). Nevertheless, due to a difficult production process (from 230U decay), availability of 226Th remains presently anecdotal with respect to the amount needed for research, and 227Th emerged as the most promising candidate.
The entry is from 10.3390/pharmaceutics13060906